Masayuki Nakano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masayuki Nakano has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Masakazu Yamamoto
Institute of Gastroenterology, Tokyo Women’s Medical University
11 shared publications - Ken Takasaki
Tokyo Women’s Medical University
7 shared publications - Satoshi Katagiri
Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
4 shared publications - Akiko Saito
Department of Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada, Shinjuku, Tokyo, 162-8666, Japan.
3 shared publications Akiko Omori
Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
2 shared publications- Hiroaki Okuda
Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
2 shared publications
Latest Publications
- 1 June 2018
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 51 (6) , 415-422
An HNF1α-Inactivated Hepatocellular Adenoma
症例は33歳の男性で,既往歴はなく,肝炎ウイルスマーカーは陰性であった.人間ドックのPETにて肝S4に高度集積(SUV max of 10.4)を認めた.血液生化学検査では,異常値は認めなかった.USでは,肝S4に径4 cm,境界が明瞭な淡いhyperechoic lesionを認めた.単純CTでは低吸収であり,動脈相で等吸収,門脈相で低吸収,遅延相で低吸収であった.EOB-MRIでは,肝細胞造影相で境界明瞭な低信号,T1脂肪抑制で低信号であり脂肪成分を含む腫瘍が考えられた.初回診断時より5か月後,悪性腫瘍が否定できないため,肝部分切除を施行した.肉眼所見では,割面は弾性軟で,黄色を呈した充実性の境界明瞭な腫瘍であった.病理診断は肝細胞腺腫(hepatocellular adenoma;以下,HCAと略記)で,免疫組織学的にHNF1α不活化型と診断した.PETで高集積となるHCAは,極めてまれであるので報告する.
- 1 June 2018
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 51 (6) , 415-422
An HNF1α-Inactivated Hepatocellular Adenoma
症例は33歳の男性で,既往歴はなく,肝炎ウイルスマーカーは陰性であった.人間ドックのPETにて肝S4に高度集積(SUV max of 10.4)を認めた.血液生化学検査では,異常値は認めなかった.USでは,肝S4に径4 cm,境界が明瞭な淡いhyperechoic lesionを認めた.単純CTでは低吸収であり,動脈相で等吸収,門脈相で低吸収,遅延相で低吸収であった.EOB-MRIでは,肝細胞造影相で境界明瞭な低信号,T1脂肪抑制で低信号であり脂肪成分を含む腫瘍が考えられた.初回診断時より5か月後,悪性腫瘍が否定できないため,肝部分切除を施行した.肉眼所見では,割面は弾性軟で,黄色を呈した充実性の境界明瞭な腫瘍であった.病理診断は肝細胞腺腫(hepatocellular adenoma;以下,HCAと略記)で,免疫組織学的にHNF1α不活化型と診断した.PETで高集積となるHCAは,極めてまれであるので報告する.
- Open Access
Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
Nonalcoholic steatohepatitis (NASH) is emerging worldwide because life-styles have changed to include much over-eating and less physical activity. The clinical and pathophysiological features of NASH are very different from those of HBV- and HCV-chronic liver diseases. The prognosis of NASH is worse among those with nonalcoholic fatty liver diseases (NAFLD), and some NASH patients show HCC with or without cirrhosis. In the present review we discuss fibrogenesis and the relationship between fibrosis and HCC occurrence in NASH to clarify the role of MMPs and TIMPs in both mechanisms. Previously we proposed MMP and TIMP expression in the multi-step occurrence of HCC from the literature based on viral-derived HCC. We introduce again these expressions during hepatocarcinogenesis and compare them to those in NASH-derived HCC, although the relationship with hepatic stem/progenitor cells (HPCs) invasion remains unknown. Signal transduction of MMPs and TIMPs is also discussed because it is valuable for the prevention and treatment of NASH and NASH-derived HCC.
Open AccessFibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
Nonalcoholic steatohepatitis (NASH) is emerging worldwide because life-styles have changed to include much over-eating and less physical activity. The clinical and pathophysiological features of NASH are very different from those of HBV- and HCV-chronic liver diseases. The prognosis of NASH is worse among those with nonalcoholic fatty liver diseases (NAFLD), and some NASH patients show HCC with or without cirrhosis. In the present review we discuss fibrogenesis and the relationship between fibrosis and HCC occurrence in NASH to clarify the role of MMPs and TIMPs in both mechanisms. Previously we proposed MMP and TIMP expression in the multi-step occurrence of HCC from the literature based on viral-derived HCC. We introduce again these expressions during hepatocarcinogenesis and compare them to those in NASH-derived HCC, although the relationship with hepatic stem/progenitor cells (HPCs) invasion remains unknown. Signal transduction of MMPs and TIMPs is also discussed because it is valuable for the prevention and treatment of NASH and NASH-derived HCC.
- 1 April 2014
- Vol. 111 (4) , 787-96
[Multiple large hepatocellular adenomas in a patient with glycogen storage disease type Ia].
A man diagnosed at birth with glycogen storage disease type Ia was found to have multiple hepatocellular adenomas at 15 years of age. At 18 years of age, he underwent transarterial tumor embolization in segments 4 and 5. At 27 years of age, the tumor in segment 4 had increased in size on follow-up computed tomography, and he was referred to our hospital. Because the tumor was large, increasing in size, and we could not exclude malignancy, we performed resection of segments 4 and 8 of the liver and partial resection of segment 5 for excisional biopsy. The pathological diagnosis was multiple inflammatory hepatocellular adenomas.
- 1 April 2014
- Vol. 111 (4) , 787-96
[Multiple large hepatocellular adenomas in a patient with glycogen storage disease type Ia].
A man diagnosed at birth with glycogen storage disease type Ia was found to have multiple hepatocellular adenomas at 15 years of age. At 18 years of age, he underwent transarterial tumor embolization in segments 4 and 5. At 27 years of age, the tumor in segment 4 had increased in size on follow-up computed tomography, and he was referred to our hospital. Because the tumor was large, increasing in size, and we could not exclude malignancy, we performed resection of segments 4 and 8 of the liver and partial resection of segment 5 for excisional biopsy. The pathological diagnosis was multiple inflammatory hepatocellular adenomas.
- Open Access
- 27 March 2013
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 49 (1) , 117-125
Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
Background Glypican-3 (GPC3) is a new prognostic factor after curative hepatectomy in patients with hepatocellular carcinoma (HCC), and the expression of GPC3 is known to be associated with postoperative metastasis. However, the role of GPC3 in patients with early HCC remains unknown. Methods We retrospectively studied 55 patients with early HCC (total 99 nodules) who underwent initial hepatectomy between 1995 and 2010. Clinicopathological features and surgical outcomes were compared in relation to GPC3 expression. Results The GPC3-positive expression was seen in 28 of 55 patients (50.9 %) with early HCC (44 of 99 nodules). The GPC3-positive expression was significantly associated with hepatitis C virus (HCV) infection (P = 0.0019) and with multiple early HCCs (P < 0.0001). The 5-year disease-free survival rate was significantly lower in patients with GPC3-positive early HCC (27 %) than in patients with GPC3-negative early HCC (62 %, P = 0.0036). The GPC3 expression was a significant independent prognostic factor for disease-free survival. However, it showed no significant difference in overall survival. Conclusions The GPC3 expression is capable to be a new prognostic factor for disease-free survival in patients with early HCC.
- 27 March 2013
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 49 (1) , 117-125
Open AccessPositive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy
Background Glypican-3 (GPC3) is a new prognostic factor after curative hepatectomy in patients with hepatocellular carcinoma (HCC), and the expression of GPC3 is known to be associated with postoperative metastasis. However, the role of GPC3 in patients with early HCC remains unknown. Methods We retrospectively studied 55 patients with early HCC (total 99 nodules) who underwent initial hepatectomy between 1995 and 2010. Clinicopathological features and surgical outcomes were compared in relation to GPC3 expression. Results The GPC3-positive expression was seen in 28 of 55 patients (50.9 %) with early HCC (44 of 99 nodules). The GPC3-positive expression was significantly associated with hepatitis C virus (HCV) infection (P = 0.0019) and with multiple early HCCs (P < 0.0001). The 5-year disease-free survival rate was significantly lower in patients with GPC3-positive early HCC (27 %) than in patients with GPC3-negative early HCC (62 %, P = 0.0036). The GPC3 expression was a significant independent prognostic factor for disease-free survival. However, it showed no significant difference in overall survival. Conclusions The GPC3 expression is capable to be a new prognostic factor for disease-free survival in patients with early HCC.
- 19 September 2009
- Vol. 56 (93) , 1086-9
Specific characteristics of scirrhous hepatocellular carcinoma.
Scirrhous hepatocellular carcinoma has been defined within general hepatocellular carcinoma. To define scirrhous hepatocellular carcinoma, the present study identified the specific characteristics as compared with general hepatocellular carcinoma. The scirrhous hepatocellular carcinoma was defined when almost all areas of the tumor were occupied with scirrhous structures. It was identified 14 patients with scirrhous hepatocellular carcinoma and 300 patients with general hepatocellular carcinoma (control), all underwent hepatectomy from 1988 to 1994. It was compared the clinical background of the patients, prognosis, and pathological features, which included immunohistological staining using Hepatocyte Paraffin 1. All scirrhous hepatocellular carcinoma showed whitish, hard forms resembling intrahepatic cholangiocarcinoma. The rates of average ICGR15, positive hepatitis C virus antibody, and microscopic invasion to the bile duct were 12%, 33%, and 20%, respectively, each significantly different than general hepatocellular carcinoma. The cumulative 10-year survival rate of scirrhous hepatocellular carcinoma and general hepatocellular carcinoma were 70% and 31%, respectively. With immunohistological staining, 43% of scirrhous hepatocellular carcinoma showed negative staining for Hepatocyte Paraffin 1. The scirrhous hepatocellular carcinoma has specific characteristics such as lower rates of hepatitis C virus infection, better prognosis, and different histological findings; therefore, scirrhous hepatocellular carcinoma should be strictly classified under a new category.
- 19 September 2009
- Vol. 56 (93) , 1086-9
Specific characteristics of scirrhous hepatocellular carcinoma.
Scirrhous hepatocellular carcinoma has been defined within general hepatocellular carcinoma. To define scirrhous hepatocellular carcinoma, the present study identified the specific characteristics as compared with general hepatocellular carcinoma. The scirrhous hepatocellular carcinoma was defined when almost all areas of the tumor were occupied with scirrhous structures. It was identified 14 patients with scirrhous hepatocellular carcinoma and 300 patients with general hepatocellular carcinoma (control), all underwent hepatectomy from 1988 to 1994. It was compared the clinical background of the patients, prognosis, and pathological features, which included immunohistological staining using Hepatocyte Paraffin 1. All scirrhous hepatocellular carcinoma showed whitish, hard forms resembling intrahepatic cholangiocarcinoma. The rates of average ICGR15, positive hepatitis C virus antibody, and microscopic invasion to the bile duct were 12%, 33%, and 20%, respectively, each significantly different than general hepatocellular carcinoma. The cumulative 10-year survival rate of scirrhous hepatocellular carcinoma and general hepatocellular carcinoma were 70% and 31%, respectively. With immunohistological staining, 43% of scirrhous hepatocellular carcinoma showed negative staining for Hepatocyte Paraffin 1. The scirrhous hepatocellular carcinoma has specific characteristics such as lower rates of hepatitis C virus infection, better prognosis, and different histological findings; therefore, scirrhous hepatocellular carcinoma should be strictly classified under a new category.
- 21 October 2004
- Published by Wiley in Journal of Surgical Oncology
- Vol. 88 (2) , 104-107
Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1
- 21 October 2004
- Published by Wiley in Journal of Surgical Oncology
- Vol. 88 (2) , 104-107
Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1
- 1 January 1999
- Published by Japan Society of Hepatology in Kanzo
- Vol. 40 (2) , 99-103
Left Supraclavicular Lymph Node Recurrence from Combined Hepatocellular and Cholangiocarcinoma. Report of a Case.
症例は71歳の男性. 1983年 (60歳), 他医にて肝後区域の門脈腫瘍栓を有する径5.5cmの肝細胞癌に対し動注化学療法が施行され腫瘍は消失た. 1991年 (68歳), 肝前区域に肝癌再発. 胆管細胞癌の術前診断で肝右葉切除が施行された. 径3.5cmの肝細胞癌 (低分化型, 索状型) と, 径3.0cmの胆管細胞癌 (中分化型管状腺癌) が衝突する肉眼像を呈し, 混合型肝癌 (combined type) と診断された. 1994年 (71歳), 術後3年目, 左頸部に径6.0cmのリンパ節転移が発見され頸部リンパ節摘出術が施行された. リンパ節の組織所見は索状および管状に増殖する腺癌で組織学的および免疫組織学的所見より胆管細胞癌からのリンパ節転移と診断された. 臨床的にはその他の部位への再発は見られず, 混合型肝癌術後左頸部リンパ節にのみ転移再発した症例と考えられた.
- 1 January 1999
- Published by Japan Society of Hepatology in Kanzo
- Vol. 40 (2) , 99-103
Left Supraclavicular Lymph Node Recurrence from Combined Hepatocellular and Cholangiocarcinoma. Report of a Case.
症例は71歳の男性. 1983年 (60歳), 他医にて肝後区域の門脈腫瘍栓を有する径5.5cmの肝細胞癌に対し動注化学療法が施行され腫瘍は消失た. 1991年 (68歳), 肝前区域に肝癌再発. 胆管細胞癌の術前診断で肝右葉切除が施行された. 径3.5cmの肝細胞癌 (低分化型, 索状型) と, 径3.0cmの胆管細胞癌 (中分化型管状腺癌) が衝突する肉眼像を呈し, 混合型肝癌 (combined type) と診断された. 1994年 (71歳), 術後3年目, 左頸部に径6.0cmのリンパ節転移が発見され頸部リンパ節摘出術が施行された. リンパ節の組織所見は索状および管状に増殖する腺癌で組織学的および免疫組織学的所見より胆管細胞癌からのリンパ節転移と診断された. 臨床的にはその他の部位への再発は見られず, 混合型肝癌術後左頸部リンパ節にのみ転移再発した症例と考えられた.